Business Overview: FOXO Technologies Inc. (NYSE American: FOXO)

---

Executive Summary

FOXO Technologies Inc. is a small, financially distressed healthcare and life-science holding company that went public via SPAC merger in 2022 on the premise of commercializing epigenetic ("biological age") biomarker science for life insurance underwriting. Since then, the original epigenetics business has stalled, and the company has pivoted largely through acquisition into a loose collection of three operating pieces: a rural Tennessee hospital and behavioral-health business (Healthcare), a biospecimen-sourcing business for biotech and pharma research (Life Science Services, via the September 2025 acquisition of Vector BioSource), and the original epigenetic diagnostics unit (Labs), which the company itself now says it cannot fund to a revenue-generating product.

FOXO matters to this universe mainly as a cautionary, honestly-reported case rather than as a growth or quality story: as of its most recent 10-K (fiscal year 2025) and subsequent H1 2026 disclosures, the company carries substantial doubt about its ability to continue as a going concern, a working-capital deficit in the tens of millions of dollars, multiple debt obligations in default, and a stock that has undergone repeated reverse splits (most recently 1-for-3,000 in June 2026) simply to try to maintain exchange listing eligibility. It is a real, SEC-reporting operating company — but a distressed micro-cap whose near-term trajectory is dominated by liquidity and capital-structure risk, not product-market execution.

---

1. Core Business Model & How They Work

FOXO no longer operates as a single coherent business; it is better understood as three loosely related units bolted together through acquisition, each with its own revenue model:

 Healthcare                    Life Science Services           Labs (Epigenetics)
 ┌───────────────────┐        ┌───────────────────────┐       ┌────────────────────┐
 │ Myrtle (substance   │        │ Vector BioSource:        │       │ Saliva-based          │
 │ use disorder        │  ➡️    │ sources & distributes    │  ➡️   │ epigenetic biomarker  │
 │ treatment, Oneida,  │        │ human biospecimens        │       │ R&D for life           │
 │ TN) + Big South Fork│        │ (blood, urine, tissue)    │       │ insurance underwriting │
 │ Medical Center      │        │ to biotech/pharma/        │       │ -- no revenue product, │
 │ (25-bed hospital,   │        │ clinical research          │       │ intangibles fully      │
 │ 24/7 ER)             │        │ customers                 │       │ impaired                │
 └───────────────────┘        └───────────────────────┘       └────────────────────┘
        │                                │                              │
        ▼                                ▼                              ▼
 Medicare/Medicaid +            Biospecimen sales to              No current revenue;
 patient service revenue        research customers                being shopped for sale
 (Tennessee-concentrated)                                          or partnership

Growth to date has come almost entirely from acquisitions funded with debt and dilutive equity (Myrtle and Rennova/Scott County Community Health in 2024, Vector BioSource in September 2025) rather than from organic expansion of any single product line, and the original "sell epigenetic risk scores to life insurers" thesis that took the company public has not produced a commercial product.

---

2. Business Segments

                         FOXO Technologies Inc.
                                  │
          ┌───────────────────────┼───────────────────────┐
          │                       │                        │
      Healthcare          Life Science Services           Labs
   (Myrtle + Big South    (Vector BioSource --          (epigenetic
    Fork Medical Center,   biospecimen sourcing,         biomarker R&D --
    rural TN)               acquired Sept. 2025)          no revenue product;
                                                           intangibles impaired)

• Healthcare: Provides substance-use-disorder treatment (residential detox/rehab for up to 30 patients, plus outpatient opiate treatment) through Myrtle, and acute/emergency care through the 25-bed Big South Fork Medical Center, a Critical Access Hospital. Added tele-specialty and cardiac diagnostic services in January 2026. Heavily dependent on Medicare/Medicaid reimbursement and concentrated in Tennessee.
• Life Science Services: Vector BioSource sources and distributes human biological specimens (blood, urine, tissue, cells) for research use to biotech, pharma, and clinical-research customers — the newest and, per management's H1 2026 commentary, fastest-growing piece, contributing to roughly 18% year-over-year net revenue growth to about $9.9 million in H1 2026.
• Labs: The original epigenetics business. The company states it "has not yet secured" the capital needed to commercialize its saliva-based biomarker science, has no timeline to a revenue-generating product, has fully impaired the division's intangible assets, and is now evaluating a sale or partnership rather than continued independent development. It is also no longer pursuing its previously licensed UCLA "epigenetic clock" patents for life insurance use.

---

3. Key Offerings

---

4. Competitive Landscape

FOXO's own 10-K devotes little space to named competitors, which itself reflects the company's distressed, sub-scale position rather than a deliberate strategic choice to omit the section.

• Life Science Services (Vector): Competes in the broader biospecimen-sourcing market against other research-sample suppliers; the 10-K describes this market generically as "competitive" without naming specific rivals.
• Healthcare: Competes for patients and payer contracts against other rural hospitals and behavioral-health providers in the Tennessee market, where reimbursement rates and Medicare/Medicaid policy, not brand competition, are the dominant pressure.
• Labs/epigenetics: The broader epigenetic and biological-age testing space includes better-funded players in consumer longevity testing, but FOXO's own filings indicate it is not currently resourced to compete commercially in this space at all — it is seeking a buyer or partner rather than competing head-on.

Given the lack of named, direct competitors in the filings and FOXO's sub-scale position in each of its three lines, a positioning matrix would overstate the rigor of the competitive analysis available; it is omitted here rather than fabricated.

---

5. Strategic Strengths & Risks

Strengths (limited and should be read skeptically):

• Revenue diversification via acquisition — moving from a single pre-revenue epigenetics bet into hospital, behavioral-health, and biospecimen revenue has produced actual, growing top-line revenue (~$9.9 million in H1 2026, up ~18% year over year) where there was previously none.
• Vector BioSource traction — the most recently acquired business appears to be the primary driver of revenue growth and is not described in going-concern terms to the same degree as the parent company overall.

Risks (real, specific, and severe):

• Going concern doubt — the FY2025 10-K and subsequent disclosures explicitly state substantial doubt about the company's ability to continue as a going concern, driven by recurring losses (net loss attributable to FOXO of $12.4 million in both 2025 and 2024) and a working-capital deficit of $25.5 million at year-end 2025, which the company reported had widened to roughly $35.9 million by mid-2026 against only about $58,000 of cash on hand.
• Debt defaults — multiple promissory notes are in default with penalty interest accruing, and the company relies on high-cost short-term and related-party funding to stay afloat.
• Equity line effectively unusable — the company's $5.0 million Strata equity line cannot currently be drawn because the stock's low price and trading volume fail the facility's draw conditions.
• Repeated reverse stock splits and dilution risk — authorized shares were raised to 25 billion, and the company has executed repeated reverse splits (most recently 1-for-3,000 in June 2026) to try to maintain listing eligibility; FINRA rejected an earlier proposed reverse split in March 2026, with an appeal pending.
• Ineffective internal controls — both internal control over financial reporting and disclosure controls were concluded not effective as of December 31, 2025.
• Concentrated control — RHI, controlled by CEO Seamus Lagan, holds majority voting power through Series A Preferred Stock, limiting other shareholders' influence, with no key-man insurance despite heavy reliance on him.
• Impaired core IP — the original epigenetics "Labs" business, the thesis the company went public on, has fully impaired intangible assets and no path to revenue absent a sale or partnership that has not yet materialized; its remaining economic upside is further capped by a license agreement limiting royalties to 3% (capped at $1.3 million).
• Pending acquisition funding gap — a pending blood-collection asset purchase reportedly requires $3.5 million in cash the company does not currently have, putting the deal at risk absent new financing.

---

6. Financial Overview

---

7. Summary Conclusion

FOXO Technologies today is less a coherent operating business than a distressed holding company that pivoted from an unfunded epigenetics thesis into a patchwork of acquired, mostly small-scale healthcare and life-science-services assets, the newest of which (Vector BioSource) is the only part showing real growth momentum. There is essentially no durable competitive moat here: no pricing power, no network effects, no meaningful switching costs, and whatever brand or IP value existed in the original epigenetics platform has been fully impaired and is now being shopped for sale or partnership rather than developed. The dominant and overwhelming forward risk is liquidity: with a working-capital deficit approaching $36 million, roughly $58,000 of cash, multiple debts already in default, an equity line that cannot currently be drawn, and explicit going-concern language from the company itself, FOXO's near-term survival as a going concern — not its competitive positioning — is the central question for anyone evaluating this stock.